BR112018005638A2 - método para aumentar o nível de cobre intracelular em um tecido isquêmico, método para entregar especificamente cobre às células de um tecido isquêmico, método para induzir pelo menos dois eventos de reparo de tecido em um tecido isquêmico, método para induzir a migração de células-tronco para um tecido isquêmico, método para promover atividades transcricionais de hif-1 dependentes de cobre em um tecido isquêmico, composição farmacêutica, uso de uma composição, composição e kit - Google Patents
método para aumentar o nível de cobre intracelular em um tecido isquêmico, método para entregar especificamente cobre às células de um tecido isquêmico, método para induzir pelo menos dois eventos de reparo de tecido em um tecido isquêmico, método para induzir a migração de células-tronco para um tecido isquêmico, método para promover atividades transcricionais de hif-1 dependentes de cobre em um tecido isquêmico, composição farmacêutica, uso de uma composição, composição e kitInfo
- Publication number
- BR112018005638A2 BR112018005638A2 BR112018005638A BR112018005638A BR112018005638A2 BR 112018005638 A2 BR112018005638 A2 BR 112018005638A2 BR 112018005638 A BR112018005638 A BR 112018005638A BR 112018005638 A BR112018005638 A BR 112018005638A BR 112018005638 A2 BR112018005638 A2 BR 112018005638A2
- Authority
- BR
- Brazil
- Prior art keywords
- ischemic tissue
- copper
- tissue
- composition
- induce
- Prior art date
Links
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title abstract 8
- 229910052802 copper Inorganic materials 0.000 title abstract 8
- 239000010949 copper Substances 0.000 title abstract 8
- 230000000302 ischemic effect Effects 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 4
- 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 title abstract 2
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 230000003834 intracellular effect Effects 0.000 title abstract 2
- 230000001737 promoting effect Effects 0.000 title abstract 2
- 230000017423 tissue regeneration Effects 0.000 title abstract 2
- 230000002103 transcriptional effect Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 title 1
- 230000012292 cell migration Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001124 trientine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
trata-se de métodos de reparo e regeneração de tecido isquêmico através da promoção da redistribuição de tecido e reuso de cobre administrando-se uma composição que compreende uma tetramina quelante de cobre, tal como trientina. métodos e composições para aumentar o nível de cobre intracelular e/ou induzir reparo de um tecido isquêmico em um indivíduo. o nível de cobre aumentado em um tecido isquêmico pode promover atividades transcricionais de hif-1 dependentes de cobre e reparo de tecido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/090528 WO2017049529A1 (en) | 2015-09-24 | 2015-09-24 | A pharmaceutical composition comprising a copper chelating tetramine and the use thereof |
| PCT/CN2016/099852 WO2017050271A1 (en) | 2015-09-24 | 2016-09-23 | Use of trientine to deliver copper to ischemic tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018005638A2 true BR112018005638A2 (pt) | 2018-10-09 |
Family
ID=58385664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018005638A BR112018005638A2 (pt) | 2015-09-24 | 2016-09-23 | método para aumentar o nível de cobre intracelular em um tecido isquêmico, método para entregar especificamente cobre às células de um tecido isquêmico, método para induzir pelo menos dois eventos de reparo de tecido em um tecido isquêmico, método para induzir a migração de células-tronco para um tecido isquêmico, método para promover atividades transcricionais de hif-1 dependentes de cobre em um tecido isquêmico, composição farmacêutica, uso de uma composição, composição e kit |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11033579B2 (pt) |
| EP (1) | EP3352743A4 (pt) |
| JP (1) | JP7041053B2 (pt) |
| KR (1) | KR20180055877A (pt) |
| CN (2) | CN117338762A (pt) |
| AU (1) | AU2016328156B2 (pt) |
| BR (1) | BR112018005638A2 (pt) |
| CA (1) | CA2998958C (pt) |
| CL (1) | CL2018000742A1 (pt) |
| CO (1) | CO2018004189A2 (pt) |
| EA (1) | EA037045B1 (pt) |
| EC (1) | ECSP18031122A (pt) |
| HK (1) | HK1259032A1 (pt) |
| IL (1) | IL257904B (pt) |
| MX (1) | MX2018003434A (pt) |
| NZ (1) | NZ740728A (pt) |
| PE (1) | PE20181166A1 (pt) |
| UA (1) | UA123503C2 (pt) |
| WO (2) | WO2017049529A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168993A1 (en) | 2015-04-22 | 2016-10-27 | Innolife Co., Ltd. | Methods of tissue repair and regeneration |
| JP2022537325A (ja) * | 2019-06-17 | 2022-08-25 | フィリーラ ニュー ジーランド リミテッド | 中枢神経系障害の併用処置 |
| KR102508657B1 (ko) * | 2021-02-17 | 2023-03-10 | 성균관대학교산학협력단 | 금-구리 나노입자를 유효성분으로 포함하는 허혈성 질환 예방 또는 치료용 조성물 |
| CA3212016A1 (en) * | 2021-03-05 | 2022-09-09 | Philera New Zealand Ltd. | Treatment of copper disorders |
| CN115554473A (zh) * | 2022-10-25 | 2023-01-03 | 华中科技大学同济医学院附属协和医院 | 去细胞心脏瓣膜复合材料及其制备方法和应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4012221A (en) | 1975-05-13 | 1977-03-15 | International Copper Research Association Inc. | Slow release copper toxicant compositions |
| US4952607A (en) | 1982-05-27 | 1990-08-28 | International Copper Research Association, Inc. | Copper complex for treating cancer |
| WO1984004922A1 (en) | 1983-06-10 | 1984-12-20 | Int Copper Ass Inc | Copper complex for treating cancer |
| PH21350A (en) | 1984-06-04 | 1987-10-13 | Smithkline Beckman Corp | Tumor cell growth imhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes |
| US4550209A (en) | 1984-07-26 | 1985-10-29 | Texaco Inc. | Process for the preparation of linear polyethylenepolyamines by reacting monoethanolamine with ethylenediamine in the presence of an intercalatively active catalyst |
| US5037812A (en) | 1985-04-02 | 1991-08-06 | Smithkline Beckman Corporation | Tumor cell growth-inhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes |
| US4806517A (en) | 1986-01-21 | 1989-02-21 | Texaco Inc. | Method for making pelleted phosphated catalysts derived from group IVB transition metal oxides and catalysts thus prepared |
| US4766247A (en) | 1986-09-26 | 1988-08-23 | Air Products And Chemicals, Inc. | Color reduction of polyamines by mild catalytic hydrogenation |
| US5385933A (en) | 1989-02-27 | 1995-01-31 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the treatment of cancer by use of the copper complex of S-(methylthio)-DL-homocysteine or the L-enantiomorph thereof |
| US5124351A (en) | 1989-02-27 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pharmaceutical compositions for the treatment of cancers susceptible to treatment with the copper complex of S-(methylthio)-DL-homocysteine or the L-enantimorph thereof |
| MX172248B (es) | 1989-12-20 | 1993-12-09 | Univ Mexico | Procedimiento para la obtencion de nuevos complejos aminoacidatos de cobre mixtos a base de fenantrolinas feniladas como agentes anticancerigenos |
| US5164367A (en) | 1990-03-26 | 1992-11-17 | Procyte Corporation | Method of using copper(ii) containing compounds to accelerate wound healing |
| US5225599A (en) | 1990-03-30 | 1993-07-06 | Union Carbide Chemicals & Plastics Technology Corporation | Selective production of linear triethylenetetramine and aminoethylethanolamine |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| US5480975A (en) | 1994-02-08 | 1996-01-02 | Brigham And Women's Hospital | Induction of vascular endothelial growth factor (VEGF) by transition metals |
| US7816403B2 (en) | 1998-09-08 | 2010-10-19 | University Of Utah Research Foundation | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same |
| US6706759B1 (en) | 1998-09-08 | 2004-03-16 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
| US6589987B2 (en) | 1998-09-08 | 2003-07-08 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using tetraethyl thiuram disulfide |
| WO2000018392A1 (en) | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine oxidase: antagonists and inhibitors |
| JP2003521453A (ja) * | 1998-09-25 | 2003-07-15 | グリコックス コーポレイション リミティド | フルクトースアミン・オキシダーゼ：アンタゴニストとインヒビター |
| CN1324931A (zh) | 2000-05-19 | 2001-12-05 | 上海博德基因开发有限公司 | 一种新的多肽——多铜氧化酶12和编码这种多肽的多核苷酸 |
| RU2183961C1 (ru) | 2001-08-27 | 2002-06-27 | Новицкий Юрий Алексеевич | Средство гидросульфат графито-металлический комплекс и способ лечения заболеваний кожи (их варианты) |
| WO2003054145A2 (en) | 2001-11-09 | 2003-07-03 | University Of Maryland, College Park | Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment |
| AU2002350170A1 (en) | 2001-11-09 | 2003-06-30 | The Johns Hopkins University | Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment |
| JP4860906B2 (ja) | 2002-03-08 | 2012-01-25 | プロテミックス コーポレイション リミティド | 心疾患および／または関連心不全の予防および／または治療 |
| AU2003214725A1 (en) * | 2002-08-20 | 2004-03-11 | Protemix Corporation Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
| CN1688301A (zh) * | 2002-08-20 | 2005-10-26 | 普罗特米克斯公司 | 药物剂型及相关的治疗用途 |
| WO2004017956A1 (en) | 2002-08-20 | 2004-03-04 | Protemix Corporation Limited | Dosage forms and related therapies |
| RS20050355A (en) | 2002-11-15 | 2007-06-04 | Ares Trading S.A., | Process for the purification of tnf- binding proteins using imac |
| CN1194668C (zh) | 2003-07-11 | 2005-03-30 | 马驷 | 纳米铜粉作为制备免疫增强药物的应用 |
| US20050159364A1 (en) | 2003-12-19 | 2005-07-21 | Cooper Garth J. | Copper antagonist compounds |
| EP1721010A2 (en) | 2004-02-24 | 2006-11-15 | Attenuon, LLC | Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents |
| US7582796B2 (en) | 2004-07-19 | 2009-09-01 | Protemix Corporation Limited | Synthesis of triethylenetetramines |
| US7618615B2 (en) * | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
| DE102004056727A1 (de) | 2004-11-24 | 2006-06-01 | Cavira Biopharmaceuticals Ag | Kupfer-Melphalan und Kupfer-Tegafur als Antitumormittel |
| WO2006104401A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
| WO2006115421A1 (en) * | 2005-04-25 | 2006-11-02 | Protemix Corporation Limited | Copper regulation evaluation and therapy |
| GB0513812D0 (en) | 2005-07-05 | 2005-08-10 | Isis Innovation | Compounds for imaging and therapy |
| WO2007055598A1 (en) | 2005-11-09 | 2007-05-18 | Protemix Corporation Limited | Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits |
| US7867522B2 (en) | 2006-09-28 | 2011-01-11 | Jr Chem, Llc | Method of wound/burn healing using copper-zinc compositions |
| CN100436457C (zh) * | 2006-12-01 | 2008-11-26 | 周成勇 | N1,n8－二取代的三乙基四胺合铜(ⅱ)配合物及其制备方法 |
| CN101322825A (zh) | 2007-06-15 | 2008-12-17 | 王振军 | 一种治疗恶性肿瘤的药物组合物 |
| RU2392668C1 (ru) | 2008-12-15 | 2010-06-20 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" | Способ индукции антипролиферативного, цитотоксического эффекта в опухолевых клетках линейных и свежевыделенных культур |
| US8999294B2 (en) | 2010-06-23 | 2015-04-07 | The Board Of Regents Of The University Of Texas System | Nanoparticles for use in tumor diagnosis and therapy |
| CN101991665B (zh) | 2010-11-15 | 2012-05-09 | 张景红 | 治疗扩张型心肌病、股骨头坏死和肿瘤的组合物及其制备工艺 |
| CN103502218B (zh) | 2011-03-04 | 2016-08-17 | 生命科技公司 | 用于缀合生物分子的化合物和方法 |
| WO2012134822A1 (en) | 2011-03-28 | 2012-10-04 | Memorial Sloan-Kettering Cancer Center | Allosteric reversible pan-caspase inhibitors |
| CN102274347B (zh) | 2011-07-15 | 2013-11-06 | 陈迪 | 抗癌组合物 |
| CN102357100A (zh) | 2011-10-12 | 2012-02-22 | 沈阳药科大学 | 抗肿瘤联合药物 |
| CN102614191A (zh) | 2012-02-29 | 2012-08-01 | 吉林大学 | 硫杂杯芳烃金属配合物的合成及作为抗癌药物的用途 |
| CN103467577B (zh) * | 2012-06-08 | 2015-07-08 | 四川大学华西医院 | 一种短肽、载铜纳米生物材料及在制备治疗下肢缺血性疾病的药物中的应用 |
| IN2014MN00938A (pt) | 2012-08-28 | 2015-04-24 | Original Biomedicals Co Ltd | |
| JP6449537B2 (ja) | 2012-12-27 | 2019-01-09 | 日本メジフィジックス株式会社 | 抗腫瘍剤、及び、抗腫瘍用キット |
| EP2948438A4 (en) | 2013-01-23 | 2016-10-05 | Univ Chicago | METHODS AND COMPOSITIONS FOR INHIBITING ATOX1 AND CCS PROTEINS INVOLVED IN COPPER TRANSFER |
| CN103265452B (zh) | 2013-05-29 | 2014-04-09 | 福州大学 | 一种希夫碱配体和其铜配合物及应用 |
| CN103467497B (zh) | 2013-09-03 | 2016-04-13 | 广西师范大学 | 以水杨醛缩牛磺酸和咪唑为配体的双配体铜配合物及其合成方法和其用途 |
| CN103788118B (zh) | 2014-02-21 | 2016-05-25 | 南开大学 | 单核铜配合物及其制备方法和应用 |
| CN103951602B (zh) | 2014-03-19 | 2016-06-15 | 河南理工大学 | 具有抗肿瘤活性的吡咯缩氨基硫脲铜、镍配合物的合成方法 |
| CN103936772A (zh) | 2014-05-05 | 2014-07-23 | 河南理工大学 | 一种具有抗肿瘤活性的双核铜配合物的制备方法 |
| CN106278907B (zh) | 2014-12-17 | 2019-06-21 | 四川科瑞德凯华制药有限公司 | 一种盐酸曲恩汀化合物 |
| WO2016168993A1 (en) | 2015-04-22 | 2016-10-27 | Innolife Co., Ltd. | Methods of tissue repair and regeneration |
-
2015
- 2015-09-24 WO PCT/CN2015/090528 patent/WO2017049529A1/en active Application Filing
-
2016
- 2016-09-23 PE PE2018000421A patent/PE20181166A1/es unknown
- 2016-09-23 BR BR112018005638A patent/BR112018005638A2/pt active Search and Examination
- 2016-09-23 WO PCT/CN2016/099852 patent/WO2017050271A1/en active Application Filing
- 2016-09-23 EP EP16848152.1A patent/EP3352743A4/en active Pending
- 2016-09-23 US US15/762,484 patent/US11033579B2/en active Active
- 2016-09-23 KR KR1020187011153A patent/KR20180055877A/ko not_active Application Discontinuation
- 2016-09-23 CA CA2998958A patent/CA2998958C/en active Active
- 2016-09-23 AU AU2016328156A patent/AU2016328156B2/en active Active
- 2016-09-23 CN CN202310915491.1A patent/CN117338762A/zh active Pending
- 2016-09-23 JP JP2018515540A patent/JP7041053B2/ja active Active
- 2016-09-23 UA UAA201804201A patent/UA123503C2/uk unknown
- 2016-09-23 MX MX2018003434A patent/MX2018003434A/es unknown
- 2016-09-23 CN CN201680056122.XA patent/CN108697669B/zh active Active
- 2016-09-23 NZ NZ740728A patent/NZ740728A/en unknown
- 2016-09-23 EA EA201890753A patent/EA037045B1/ru not_active IP Right Cessation
-
2018
- 2018-03-06 IL IL257904A patent/IL257904B/en active IP Right Grant
- 2018-03-21 CL CL2018000742A patent/CL2018000742A1/es unknown
- 2018-04-20 CO CONC2018/0004189A patent/CO2018004189A2/es unknown
- 2018-04-20 EC ECIEPI201831122A patent/ECSP18031122A/es unknown
-
2019
- 2019-01-29 HK HK19101520.6A patent/HK1259032A1/zh unknown
-
2021
- 2021-05-10 US US17/316,577 patent/US20210379102A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL257904B (en) | 2021-04-29 |
| US11033579B2 (en) | 2021-06-15 |
| CA2998958C (en) | 2020-12-22 |
| CN108697669A (zh) | 2018-10-23 |
| AU2016328156B2 (en) | 2022-03-17 |
| US20210379102A1 (en) | 2021-12-09 |
| EA037045B1 (ru) | 2021-01-29 |
| AU2016328156A1 (en) | 2018-04-12 |
| NZ740728A (en) | 2019-07-26 |
| IL257904A (en) | 2018-05-31 |
| WO2017049529A1 (en) | 2017-03-30 |
| PE20181166A1 (es) | 2018-07-19 |
| CL2018000742A1 (es) | 2018-11-09 |
| KR20180055877A (ko) | 2018-05-25 |
| MX2018003434A (es) | 2018-11-09 |
| UA123503C2 (uk) | 2021-04-14 |
| CO2018004189A2 (es) | 2018-07-19 |
| JP2018531931A (ja) | 2018-11-01 |
| EP3352743A1 (en) | 2018-08-01 |
| CN108697669B (zh) | 2023-08-15 |
| US20180296598A1 (en) | 2018-10-18 |
| CN117338762A (zh) | 2024-01-05 |
| ECSP18031122A (es) | 2018-05-31 |
| CA2998958A1 (en) | 2017-03-30 |
| JP7041053B2 (ja) | 2022-03-23 |
| HK1259032A1 (zh) | 2019-11-22 |
| EA201890753A1 (ru) | 2018-08-31 |
| WO2017050271A1 (en) | 2017-03-30 |
| EP3352743A4 (en) | 2019-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018005638A2 (pt) | método para aumentar o nível de cobre intracelular em um tecido isquêmico, método para entregar especificamente cobre às células de um tecido isquêmico, método para induzir pelo menos dois eventos de reparo de tecido em um tecido isquêmico, método para induzir a migração de células-tronco para um tecido isquêmico, método para promover atividades transcricionais de hif-1 dependentes de cobre em um tecido isquêmico, composição farmacêutica, uso de uma composição, composição e kit | |
| CL2018000897A1 (es) | Composicion de fortalecimiento del cabello y metodo para fortalecer el cabello. | |
| BR112019005595A2 (pt) | compostos e métodos para modulação de ido e tdo, e indicações para os mesmos | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| BR112018073328A2 (pt) | combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade | |
| CL2017003456A1 (es) | Metodos para tratar tumores de celulas epitelioides | |
| CR20170478A (es) | Compuestos novedosos | |
| GT201400043A (es) | Imidazopiridazinas sustituidas con amino | |
| BR112016023851A2 (pt) | ?composição de revestimento de duas partes e método para revestir uma superfície? | |
| BR112017014218A2 (pt) | método para a oxidação eletroquímica, célula eletroquímica, método para a oxidação fotoeletroquímica e célula fotoeletroquímica | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| PE20180399A1 (es) | Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas | |
| BR112018009311A8 (pt) | ?método para tratar um sujeito humano sofrendo de tma persistente associada com transplante de célula tronco hematopoiética? | |
| DOP2017000146A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| MX2020003605A (es) | Manipulación del metabolismo de triptamina. | |
| AR101449A1 (es) | Inhibidores de myh7b y usos de los mismos | |
| PE20181137A1 (es) | Metodos moleculares de aseguramiento de la calidad para su uso en la secuenciacion | |
| BR112017017720A2 (pt) | composição ácida baseada em leonardita e aminoácidos | |
| CO2020007044A2 (es) | Derivados de pirrol como inhibidores de acc | |
| CO7141430A2 (es) | Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación | |
| CO2019006424A2 (es) | Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas | |
| BR112018014540A2 (pt) | formulações/composições compreendendo inibidor de btk | |
| BR112017017071A2 (pt) | nova lisina descarboxilase, e método para produzir cadaverina utilizando a mesma | |
| BR112018000841A8 (pt) | Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites | |
| AR112069A1 (es) | Inmunoglobulinas que fijan aggrecan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |